MTM Investment Management LLC Sells 99 Shares of Zoetis Inc. (NYSE:ZTS)

MTM Investment Management LLC cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 2.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,320 shares of the company’s stock after selling 99 shares during the quarter. MTM Investment Management LLC’s holdings in Zoetis were worth $704,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in ZTS. Atlantic Edge Private Wealth Management LLC boosted its position in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in shares of Zoetis during the third quarter valued at approximately $31,000. First Personal Financial Services bought a new stake in shares of Zoetis during the third quarter valued at approximately $33,000. Capital Performance Advisors LLP bought a new stake in shares of Zoetis during the third quarter valued at approximately $33,000. Finally, Dunhill Financial LLC boosted its holdings in Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. UBS Group assumed coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Morgan Stanley dropped their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Stifel Nicolaus dropped their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Leerink Partners assumed coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Finally, Piper Sandler lowered their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a report on Monday. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $214.00.

Zoetis Stock Down 0.2 %

Zoetis stock opened at $173.99 on Thursday. The stock has a market cap of $78.50 billion, a PE ratio of 32.70, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The stock has a fifty day moving average of $169.11 and a 200 day moving average of $179.11.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.15%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 37.59%.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.